Candace S. Johnson, Ph.D., President and Chief Executive Officer of Roswell Park Cancer Institute in Buffalo, N.Y., is a founder of OmniSeq and serves as an integral part of the continuum between Roswell and OmniSeq.
Carl Morrison, MD, DVMPresident, CSO and Founder
Dr. Morrison is OmniSeq’s Founder and Chief Scientific Officer. Dr. Morrison is a board-certified pathologist and Executive Director of the Center for Personalized Medicine at Roswell Park Cancer Institute (RPCI) in Buffalo, New York. Dr. Morrison is a Professor and Program Member in Cancer Genetics at RPCI and was recently awarded Roswell Park’s prestigious Thomas B. Tomasi Hope Award for his contribution to cancer research.
Recognized nationally for his work in translational medicine, Dr. Morrison has authored or co-authored more than 100 peer-reviewed manuscripts with a focus on molecular pathology. His work has been published in many leading journals, including Nature, the Journal of Clinical Oncology, and Cancer Research.
Dr. Morrison is a Member of the College of American Pathologists and the Association for Molecular Pathology.
Antonios Papanicolau-Sengos, MDAsst Director of Clinical Laboratory
Dr. Papanicolau-Sengos became a Laboratory Director at OmniSeq after transitioning from Roswell Park Cancer Institute (RPCI). He oversees the implementation of clinical testing and signs the bulk of the clinical assays performed at OmniSeq. He has extensive experience with current molecular techniques such as nCounter and next-generation sequencing technologies. As Laboratory Director he also manages day-to-day laboratory operations and regulatory compliance.
Dr. Papanicolau-Sengos is boarded on Anatomic, Clinical, and Molecular and Genetic Pathology by the American Board of Pathology. He is a member of multiple professional organizations, including the College of American Pathologists and Association of Molecular Pathology.
Dr. Papanicolau-Sengos has a Master’s in molecular biology which he received from University of Maryland, Baltimore County. He completed his medical training at Georgetown School of Medicine and his Anatomic and Clinical Pathology training at University of California San Diego. After a general surgical pathology fellowship at University of Washington, he completed his training with a Molecular Genetic Pathology fellowship at Associated Regional and University Pathologists (ARUP) laboratories.
Jeffrey ConroySenior Vice President of Technology Development
Jeffrey Conroy serves as Senior Vice President of Technology Development for OmniSeq Precision Medicine Technology. He leads the OmniSeq research and clinical laboratory development team by integrating company processes with the appropriate science, partners, and technologies. He provides vision and leadership for developing and implementing advanced diagnostic tests from target design through validation as a clinical assay.
Prior to joining OmniSeq, Jeff spent three years as Director of Genomic Technologies in the Center for Personalized Medicine at Roswell Park Cancer Institute. During his career at Roswell, he also served 15 years as Co-Director of the Genomics Shared Resource, overseeing its expansion to more than 50 genomics-based service offerings and a user base of 200+ investigators per year.
Jeff was Supervisor of the Molecular Cytogenetics Laboratory at University Hospitals of Cleveland from 1992-1996, where he developed and implemented some of the earliest molecular diagnostic laboratory-developed tests. He began his career with the Children’s Hospital of Buffalo in the Robert Guthrie Biochemical & Molecular Genetics Laboratory. He received a Bachelor of Science degree in Medical Technology from the State University of New York College at Fredonia.
OmniSeq Board of Directors
Buford Sears is KeyBank N.A. Regional President and divisional manager for WNY, in charge of commercial lending in WNY and Western Pennsylvania, RPCI Board Member, Chair RPCI Finance Committee, with expertise in commercial real estate equipment financing, as well as healthcare and government banking activities.
Kenneth A. Manning is a partner with Phillips Lytle LLP, with experience in corporate litigation, personal injury litigation and class actions that is represented by his status as member emeritus for the Dean’s Advisory Council of University at Buffalo Law School.
Ronnie Andrews is the founder of the Bethesda Group, a healthcare consulting company that provides advisory services to molecular diagnostic start-up companies. Previously, Ronnie held various executive and C-suite positions for molecular diagnostics companies including Thermo Fisher Scientific, Life Technologies, Roche Diagnostics, Roche Molecular, Immucor, and Abbott Diagnostics. Ronnie was the CEO of Clarient, Inc. (NASDAQ:CLRT) for six years until it was sold to GE Healthcare.
Paul Billings, MD, Ph.D, FACP, FACGMP is a Board certified internist and clinical geneticist. Dr. Billings is the Chairman of Biological Dynamics, Inc., an innovative cancer testing company in San Diego, CA. Recently, he completed significant consultancies at Johnson & Johnson and Thermo Fisher Scientific (creating and directing the IMPACT Cancer Program). He has held academic appointments at Harvard University, U.C. San Francisco, Stanford University and U.C. Berkeley.
Carl Morrison is a board-certified pathologist, who developed the vision for OmniSeq while leading the Center for Personalized Medicine and Division of Molecular Pathology at RPCI.
Mark Gardner is the Chief Executive Officer of OmniSeq Precision Medicine Technology and a member of our Board of Directors. Prior to joining OmniSeq, Mark spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies). Most recently, Mark was the Vice President and General Manager of the Ion Torrent business unit at Thermo Fisher. Prior to Thermo Fisher, Mark was a Six Sigma Master Black Belt at General Electric, an entrepreneur at two start-up companies, a management consultant at McKinsey and Company, and a Navy Pilot. Mark is responsible for financing the company, and managing the executive team.
Mark earned an MBA in Finance with Palmer Scholar Distinction from the Wharton School of Business, an MA in National Security Studies from Georgetown University, and a BS with Distinction from the US Naval Academy.
OmniSeq Executive Team
Margot Schoenborn - Chief Administrative Officer, General Counsel, Compliance and Privacy Officer, and Corporate Secretary
Margot Schoenborn serves as Chief Administrative Officer, General Counsel, and Corporate Secretary at OmniSeq Precision Medicine Technology. She is responsible for leading corporate strategic and tactical legal initiatives that protect and preserve the legal, ethical, and financial integrity of OmniSeq, including handling corporate governance and risk management issues, commercial transactions, intellectual property, and research partnerships. Margot is responsible for finance, administrative IT, legal, operations, human resources and program portfolio management departments.
Margot joined OmniSeq from the Roswell Park Cancer Institute where she served most recently as Deputy General Counsel.
Before joining Roswell Park, Margot was a Special Assistant Attorney General in the New York State Office of the Attorney General’s Medicaid Fraud Control Unit (MFCU). During her tenure with the MFCU, Margot was appointed by the National Association of Medicaid Fraud Control Units to represent national Medicaid interests in multi-state investigations and global settlements in pharmaceutical and diagnostic provider qui tam cases.
Prior to that, Margot was an Assistant U.S. Attorney for the Eastern District of New York, where she specialized in health-care fraud investigations. Before her role with the U.S. Attorney’s Office, Margot was a commercial litigator with Nixon Peabody’s NYC office.
Margot received her Bachelor’s degree from Nazareth College, followed by her Doctor of Law (JD) degree from the State University of New York at Buffalo.
Matt Klusas serves as Chief Commercial Officer for OmniSeq Precision Medicine Technology. He leads the OmniSeq sales, marketing, business development, billing, managed care, and customer service functions. Prior to joining OmniSeq, Matt was most recently at Thermo Fisher Scientific, where he led a business focusing on large scale deployments of genetic analysis technologies, including next generation DNA sequencing, Capillary Electrophoresis sequencing, qPCR, and other technologies. Prior to Thermo Fisher Scientific, Matt held management roles at the American Type Culture Collection (ATCC), Life Technologies, and McKinsey & Co. Matt was published in the Journal of Commercial Biotechnology, the McKinsey Quarterly, and the Credit Union Journal. In 2015, Illinois State University selected him the Young Alumni of the Year. He received an MSc in Economic History from the London School of Economics and a BS in Communication from the Illinois State University. He also studied at Magdalen College, University of Oxford.
Prior to joining OmniSeq, Mary Nesline played several roles at Roswell Park Cancer Institute (RPCI), including Director of Clinical Support Informatics for the Center for Personalized Medicine where she led analytics for the clinical validation of OmniSeq Target. As Co-Director of the Institute’s Data Bank and BioRepository, Mary was responsible for building the resource from the ground up and leading national Comprehensive Cancer Center Support Grant (CCSG) submissions. She also lead a cross-functional Institutional team of stakeholders and staff to design and implement an enterprise level laboratory information system (LIMS) driven biorepository program – tracking and managing informed consent, protocols, collection and banking millions of biospecimens and associated clinical and epidemiological data annotation to accelerate efficient and ethical support of hundreds of translational cancer research studies, grants and collaborations from genesis through publication.
Mary holds a Master’s of Science degree in Epidemiology from the State University of New York at Buffalo. She spent 10 years in the primary care setting as a researcher and health policy analyst designing, operating, and assessing intervention programs, novel service delivery and reimbursement models, grants and contracts with managed care plans that targeted vulnerable and underserved populations in partnership with federal and state agencies including the NYSDOH, NYS Insurance Department, NYS and County Departments of Social Services, the Bureau of Primary Care and the Office of Rural Health Policy.
As Senior Vice President of Knowledge Informatics, Mary is the engineer behind the clinical genomics learning information system for OmniSeq Precision Medicine Technology. She leads the team responsible for capturing, curating, surfacing, integrating and managing the quality of clinical evidence content and data throughout OmniSeq solutions from initial physician interface through bioinformatics and reporting. Mary ensures the vision for a flexible and scalable molecular diagnostics-centered informatics solution that creates genomic data assets and product value by rapidly generating and applying evidence of clinical utility from genomic testing to physicians, informing product and business development and managed care coverage policies, and driving R&D.
Colleen serves as an internal resource for strategy development. She leads executive recruitment, human resource management, and administrative functions.
Colleen believes that a culture of learning and collaboration is necessary for OmniSeq to remain on the leading edge of genomic medicine. To that end, she strives to create an organization that embraces equity, diversity, and inclusion.
She takes a multi-faceted approach to career development, finding innovative policies and strategies to recruit, train, and retain talented staff. As OmniSeq continues to grow, she continually seeks career path opportunities for our associates. In addition, Colleen is committed to the idea that building a supportive, adaptable, and productive workplace culture is absolutely essential to attract the talent who will lead our organization in the future.
Colleen has over 25 years of experience in business leadership. Previously, as Senior Vice President and Consumer Market Executive at Bank of America, she was responsible for delivering excellence in sales, customer service, associate satisfaction, and operations for the western New York market. She was also actively involved in leadership coaching and development.
As Vice President of Bioinformatics, Dr. Ji He leads the R&D work of OmniSeq Precision Medicine Technology for its molecular diagnostic assay development programs, and oversees the Bioinformatics support work in the company’s production operations. Ji heads the clinical study planning and analyses, and is responsible for developing and validating OmniSeq’s molecular diagnostic and next generation sequencing analysis pipelines. He also plays a central role in evaluating and implementing new lab testing approaches and strategies for the company’s evolving product portfolio.
Ji has more than 12 years of post-doctoral experience in Computer Science and Bioinformatics, with applications ranging from plant genomics research, cancer research and clinical molecular diagnostics. Prior to joining OmniSeq, Ji was the Bioinformatics Director with BioReference Laboratories, Inc. Previous to that he served as Bioinformatics Manager at Leidos Biomedical Research Inc. for the National Cancer Institute, and held several management roles with the Samuel Roberts Noble Foundation, Inc., including Director of Scientific Computing.
Ji received his Bachelor’s degree in Electronics Engineering and Master’s degree in Information Science and Information Management from Shanghai Jiao Tong University, and his Ph.D. degree in Computer Science from the National University of Singapore. Ji has published more than 40 scientific papers in machine learning algorithms, bioinformatics applications and cancer research.
Dr. Glenn is responsible for leadership of the R&D staff which is responsible for identifying and developing the next level of clinical tests needed to service the oncology field. Within this role he is responsible for maintaining the lab at the forefront of technological advances and is focused on developing the most state-of-the-art cost effective solution for clinical testing. This includes maintaining an up to date knowledge of all leading edge technologies and focusing on novel scientific findings which are continually evolving. The dual role Sean possesses as Director of RPCI’s Genomics Shared Resource and as OmniSeq’s Director of R&D proffers a unique ability to transition basic research concepts, findings, and technologies into translational practices with the development of new clinical tests that will be added to OmniSeq’s portfolio.
Dr. Glenn as the Director of the Genomics Shared Resource (GSR) at Roswell Park Cancer Institute, is responsible for the leadership of the core facility. He has full operational leadership of the entire staff ,and oversees the day-to-day activities, including the GSR LIMS, sample workflow, reports, budgets, protocol development, personnel, maintenance, regulations, billing, purchases, and customer service. Dr. Glenn interacts with investigators and the Bioinformatics Resource staff to help develop projects utilizing advanced technologies in the ever growing field of genomics. Currently, he also has a faculty appointment within the department of Molecular and Cellular Biology where he focuses on the use of Next Generation Sequencing (NGS) applications in collaboration with mouse modelling for understanding the genetic landscape which drives metastatic disease.
Sean received a Bachelor’s of Science in Biology from the State University of New York at Buffalo where he studied the RIP function in Neurospora crassa which is a duplication and mutation event localized to the premeiotic cells of the life cycle. He then went on to earn a Master’s of Science from the University at Buffalo focusing on transcriptional regulation of genes responsible for vascular development. Sean received a PhD in Molecular and Cellular Biology from the Roswell Park Cancer Institute Division of the University of Buffalo where he developed a mouse model that mimics human metastatic pancreatic neuroendocrine carcinoma. This model, coupled with NGS technology, is a powerful tool for studying the cooperating mutations responsible for the evolution of metastatic disease including the identification and the role circulating tumor cells play in the progression of this process. This model also offers great promise for studying the pharmaceutical intervention of the metastatic phenotype.